Considering the differences in metabolic patterns between normal cells and cancer cells, at this time, if the activator of SIRT3 is combined, the anti-tumor effect of paclitaxel and platinum can be enhanced not only by activating programmed cell death (apoptosis, autophagy associated cell death), but also by enhancing the mitochondrial function of nerve cells to reduce the neurotoxicity of chemotherapy drugs. The gene discussed is SIRT3; the disease is cancer.